8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 17, 2026·SEC
Material company update
Apr 16, 2026·SEC
Revolution Medicines, Inc.(RVMD)Earnings, Financials & Key Ratios
RVMD•NASDAQ
Price updated Jun 19, 2026
AboutRevolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Show more
- Revenue$0
- EBITDA-$1.17B-72.0%
- Net Income-$1.13B-88.5%
- EPS (Diluted)-5.95-66.2%
- ROE-58.07%-98.0%
RVMD Key Insights
Revolution Medicines, Inc. (RVMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 95 (top 5%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Profits declining 59.9% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 13.3% in last year
- ✗Expensive at 19.0x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RVMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RVMD Price & Volume
Revolution Medicines, Inc. (RVMD) stock price & volume — 10-year historical chart
Loading chart...
RVMD Growth Metrics
Revolution Medicines, Inc. (RVMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-96.66%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-77.31%
Return on Capital
10 Years-80.65%
5 Years-37.82%
3 Years-40.51%
Last Year-53.04%
RVMD Recent Earnings
Revolution Medicines, Inc. (RVMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 2/12 qtrs (67%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$2.29-24.5%
$1.84
Rev
—
$2M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$1.86-17.7%
$1.58
Rev
—
$4M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$1.61-13.4%
$1.42
Rev
—
$2M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$1.31-39.4%
$0.94
Rev
—
$28M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $2.29vs $1.84-24.5% | —vs $2M |
| Q1 2026 | Feb 25, 2026 | $1.86vs $1.58-17.7% | —vs $4M |
| Q4 2025 | Nov 5, 2025 | $1.61vs $1.42-13.4% | —vs $2M |
| Q3 2025 | Aug 6, 2025 | $1.31vs $0.94-39.4% | —vs $28M |
Based on last 12 quarters of dataView full earnings history →
RVMD Peer Comparison
Revolution Medicines, Inc. (RVMD) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MRSN | 145.36M | 29.08 | -2.06 | 9.88% | -211.21% | -5.05% | ||
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 | |
 BDTX | 95.12M | 1.66 | 4.26 | -36.37% | 0.13 | |||
 TNGX | 3.25B | 27.97 | -32.15 | 48.29% | -188.15% | -41.54% | 0.10 | |
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 AMGN | 182.2B | 337.60 | 23.72 | 9.92% | 20.95% | 89.41% | 6.31 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 |
Compare RVMD vs Peers
Revolution Medicines, Inc. (RVMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RVMD Income Statement
Revolution Medicines, Inc. (RVMD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 20.16M | 50.04M | 42.98M | 29.39M | 35.38M | 11.58M | 0 | 0 | 0 |
Revenue Growth % | - | - | 148.16% | -14.1% | -31.62% | 20.38% | -67.27% | -100% | - | - |
Cost of Goods Sold | 26.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.56M | 4.7M |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -26.59M▲ 0% | 20.16M▲ 175.8% | 50.04M▲ 148.2% | 42.98M▼ 14.1% | 29.39M▼ 31.6% | 35.38M▲ 20.4% | 11.58M▼ 67.3% | 0▼ 100.0% | -16.56M▲ 0% | -4.7M▲ 0% |
Gross Margin % | - | 100% | 100% | 100% | 100% | 100% | 100% | - | - | - |
Gross Profit Growth % | - | 175.85% | 148.16% | -14.1% | -31.62% | 20.38% | -67.27% | -100% | - | - |
Operating Expenses | 4.54M | 60.49M | 104.16M | 153.68M | 217.4M | 293.66M | 498.76M | 689.52M | 1.17B | 1.38B |
OpEx % of Revenue | - | 300% | 208.15% | 357.54% | 739.7% | 830.01% | 4307.12% | - | - | - |
Selling, General & Admin | 4.54M | 9.41M | 12.41M | 21.43M | 30.45M | 40.59M | 75.62M | 97.3M | 187.13M | 258.91M |
SG&A % of Revenue | - | 46.66% | 24.79% | 49.85% | 103.61% | 114.71% | 653.03% | - | - | - |
Research & Development | 26.59M | 51.08M | 91.75M | 132.25M | 186.95M | 253.07M | 423.14M | 592.23M | 978.68M | 1.12B |
R&D % of Revenue | - | 253.33% | 183.36% | 307.68% | 636.09% | 715.3% | 3654.09% | - | - | - |
Other Operating Expenses | -26.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -31.13M▲ 0% | -40.33M▼ 29.6% | -54.12M▼ 34.2% | -110.7M▼ 104.5% | -188.01M▼ 69.8% | -258.28M▼ 37.4% | -487.19M▼ 88.6% | -689.52M▼ 41.5% | -1.18B▼ 71.5% | -1.39B▲ 0% |
Operating Margin % | - | -199.99% | -108.15% | -257.54% | -639.7% | -730.01% | -4207.12% | - | - | - |
Operating Income Growth % | - | -29.55% | -34.2% | -104.54% | -69.84% | -37.38% | -88.63% | -41.53% | -71.48% | - |
EBITDA | -29.94M | -38.56M | -50.78M | -104.15M | -180.68M | -248.62M | -477.88M | -677.7M | -1.17B | -1.37B |
EBITDA Margin % | - | -191.25% | -101.47% | -242.31% | -614.75% | -702.72% | -4126.74% | - | - | - |
EBITDA Growth % | - | -28.8% | -31.67% | -105.11% | -73.47% | -37.61% | -92.21% | -41.82% | -72.02% | -76.91% |
D&A (Non-Cash Add-back) | 1.19M | 1.76M | 3.34M | 6.54M | 7.33M | 9.66M | 9.31M | 11.82M | 16.56M | 12.84M |
EBIT | -31.02M | -41.67M | -51.93M | -108.46M | -187.08M | -258.28M | -487.19M | -689.52M | -1.11B | -911.45M |
Net Interest Income | 2K | 661K | 2.08M | 2.17M | 917K | 9.15M | 47.18M | 86.88M | 66.46M | 42.41M |
Interest Income | 105K | 777K | 2.19M | 2.24M | 929K | 9.15M | 47.48M | 86.88M | 90.69M | 85.29M |
Interest Expense | 103K | 116K | 106K | 71K | 12K | 0 | 303K | 0 | 24.23M | 11.17M |
Other Income/Expense | 2K | -1.46M | 2.08M | 2.17M | 917K | 9.15M | 47.29M | 88.68M | 51.07M | 15.13M |
Pretax Income | -31.13M▲ 0% | -41.79M▼ 34.3% | -52.04M▼ 24.5% | -108.53M▼ 108.6% | -187.09M▼ 72.4% | -249.13M▼ 33.2% | -439.89M▼ 76.6% | -600.85M▼ 36.6% | -1.13B▼ 88.3% | -1.37B▲ 0% |
Pretax Margin % | - | -207.24% | -103.99% | -252.5% | -636.58% | -704.14% | -3798.71% | - | - | - |
Income Tax | 105K | 0 | -4.37M | -371K | 0 | -420K | -3.52M | -753K | 0 | 0 |
Effective Tax Rate % | -0.34% | 0% | 8.4% | 0.34% | 0% | 0.17% | 0.8% | 0.13% | 0% | 0% |
Net Income | -31.13M▲ 0% | -41.79M▼ 34.3% | -47.66M▼ 14.1% | -108.16M▼ 126.9% | -187.09M▼ 73.0% | -248.71M▼ 32.9% | -436.37M▼ 75.5% | -600.09M▼ 37.5% | -1.13B▼ 88.5% | -1.37B▲ 0% |
Net Margin % | - | -207.24% | -95.25% | -251.63% | -636.58% | -702.95% | -3768.28% | - | - | - |
Net Income Growth % | - | -34.25% | -14.06% | -126.92% | -72.98% | -32.93% | -75.46% | -37.52% | -88.52% | -96.66% |
Net Income (Continuing) | -31.13M | -41.79M | -47.66M | -108.16M | -187.09M | -248.71M | -436.37M | -600.09M | -1.13B | -1.37B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.85▲ 0% | -1.15▼ 35.3% | -1.31▼ 13.9% | -1.62▼ 23.7% | -2.47▼ 52.5% | -3.08▼ 24.7% | -3.86▼ 25.3% | -3.58▲ 7.3% | -5.95▼ 66.2% | -6.92▲ 0% |
EPS Growth % | - | -35.29% | -13.91% | -23.66% | -52.47% | -24.7% | -25.32% | 7.25% | -66.2% | -77.31% |
EPS (Basic) | -0.85 | -1.15 | -1.31 | -1.62 | -2.47 | -3.08 | -3.86 | -3.58 | -5.95 | - |
Diluted Shares Outstanding | 36.47M | 36.47M | 36.47M | 66.6M | 72.81M | 80.63M | 113.15M | 167.74M | 190.13M | 198.1M |
Basic Shares Outstanding | 36.47M | 36.47M | 36.47M | 66.6M | 72.81M | 80.63M | 113.15M | 167.74M | 190.13M | 198.1M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RVMD Balance Sheet
Revolution Medicines, Inc. (RVMD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 9.44M | 85.43M | 133.98M | 454.12M | 589.77M | 660.18M | 1.88B | 2.33B | 2.08B | 1.97B |
Cash & Short-Term Investments | 9.08M | 69.59M | 122.76M | 440.74M | 577.05M | 644.94M | 1.85B | 2.29B | 2.03B | 1.91B |
Cash Only | 9.08M | 69.59M | 16.66M | 104.27M | 108.5M | 161.41M | 696.15M | 543.06M | 383.75M | 440.94M |
Short-Term Investments | 0 | 0 | 106.1M | 336.47M | 468.56M | 483.53M | 1.16B | 1.75B | 1.64B | 1.47B |
Accounts Receivable | 0 | 7.3M | 8.74M | 6.39M | 5.93M | 4.67M | 1.25M | 0 | 0 | 0 |
Days Sales Outstanding | - | 132.19 | 63.73 | 54.29 | 73.63 | 48.21 | 39.53 | - | - | - |
Inventory | 0 | 6.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 6.6M | 0 | 0 | 0 | 10.57M | 25.07M | 38.33M | 49.36M | 59.83M |
Total Non-Current Assets | 5.64M | 85.16M | 86.55M | 113.28M | 148.22M | 151.75M | 182.42M | 230.67M | 279.47M | 285.82M |
Property, Plant & Equipment | 5.25M | 6.87M | 7.15M | 36.34M | 71.24M | 73.74M | 100.01M | 141.82M | 165.28M | 161.37M |
Fixed Asset Turnover | - | 2.93x | 7.00x | 1.18x | 0.41x | 0.48x | 0.12x | - | - | 0.00x |
Goodwill | 0 | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M |
Intangible Assets | 0 | 63.08M | 62.01M | 60.95M | 59.88M | 58.81M | 57.74M | 56.67M | 55.8M | 55.8M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 383K | 593K | 2.78M | 1.39M | 2.5M | 4.59M | 10.06M | 17.57M | 43.78M | 54.05M |
Total Assets | 15.08M▲ 0% | 170.59M▲ 1031.4% | 220.53M▲ 29.3% | 567.4M▲ 157.3% | 737.99M▲ 30.1% | 811.93M▲ 10.0% | 2.06B▲ 153.9% | 2.56B▲ 24.1% | 2.35B▼ 8.0% | 2.25B▲ 0% |
Asset Turnover | - | 0.12x | 0.23x | 0.08x | 0.04x | 0.04x | 0.01x | - | - | 0.00x |
Asset Growth % | - | 1031.43% | 29.28% | 157.29% | 30.06% | 10.02% | 153.93% | 24.09% | -7.97% | 49.39% |
Total Current Liabilities | 7.6M | 30.55M | 43.05M | 47.18M | 60.35M | 61.98M | 143.85M | 163.91M | 290.42M | 289.6M |
Accounts Payable | 3.35M | 5.24M | 11.4M | 12.61M | 14.06M | 21.31M | 61.79M | 54.43M | 64.62M | 80.54M |
Days Payables Outstanding | 46.03 | - | - | - | - | - | - | - | 1.42K | 5.37K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.47M | 16.61M |
Deferred Revenue (Current) | 0 | 16.83M | 17.12M | 12.11M | 12.36M | 4.46M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2.55M | 6.06M | 5.73M | 7.83M | 10.16M | 13.79M | 27.51M | 31.36M | 209.34M | 192.45M |
Current Ratio | 1.24x | 2.80x | 3.11x | 9.63x | 9.77x | 10.65x | 13.06x | 14.20x | 7.14x | 6.80x |
Quick Ratio | 1.24x | 2.58x | 3.11x | 9.63x | 9.77x | 10.65x | 13.06x | 14.20x | 7.14x | 6.80x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 2.95M | 43.38M | 24.94M | 45.55M | 75.07M | 64.76M | 91.66M | 129.18M | 432.79M | 464.22M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 142.23M | 140.02M |
Capital Lease Obligations | 0 | 0 | 0 | 28.99M | 60.42M | 57.43M | 80.58M | 122.97M | 0 | 261.83M |
Deferred Tax Liabilities | 0 | 12.19M | 7.82M | 7.44M | 7.44M | 7.03M | 3.12M | 2.35M | 2.35M | 7.06M |
Other Non-Current Liabilities | 2.95M | 2.77M | 2.4M | 632K | 634K | 301K | 7.97M | 3.86M | 288.2M | 321.85M |
Total Liabilities | 10.55M | 73.93M | 67.99M | 92.72M | 135.42M | 126.74M | 235.51M | 293.1M | 723.21M | 753.82M |
Total Debt | 0 | 147K | 0 | 32.66M | 66.63M | 64.2M | 87.94M | 135.84M | 158.7M | 156.63M |
Net Debt | -9.08M | -69.44M | -16.66M | -71.6M | -41.86M | -97.21M | -608.2M | -407.22M | -225.04M | -284.31M |
Debt / Equity | - | 0.00x | - | 0.07x | 0.11x | 0.09x | 0.05x | 0.06x | 0.10x | 0.10x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.11x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.21x |
Interest Coverage | -301.20x | -359.25x | -489.92x | -1527.59x | -15589.92x | - | -1607.87x | - | -45.69x | -81.62x |
Total Equity | 4.53M▲ 0% | 96.66M▲ 2033.3% | 152.53M▲ 57.8% | 474.68M▲ 211.2% | 602.57M▲ 26.9% | 685.19M▲ 13.7% | 1.83B▲ 166.5% | 2.27B▲ 24.0% | 1.63B▼ 28.0% | 1.5B▲ 0% |
Equity Growth % | - | 2033.28% | 57.81% | 211.19% | 26.94% | 13.71% | 166.52% | 24.04% | -27.98% | -38.63% |
Book Value per Share | 0.12 | 2.65 | 4.18 | 7.13 | 8.28 | 8.50 | 16.14 | 13.50 | 8.58 | 7.57 |
Total Shareholders' Equity | 4.53M | 96.66M | 152.53M | 474.68M | 602.57M | 685.19M | 1.83B | 2.27B | 1.63B | 1.5B |
Common Stock | 0 | 0 | 0 | 7K | 8K | 9K | 16K | 18K | 19K | 19K |
Retained Earnings | -67.93M | -109.72M | -157.39M | -265.55M | -452.64M | -701.34M | -1.14B | -1.74B | -2.87B | -3.32B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 74K | 116K | -376K | -1.78M | 544K | 1.32M | 3.24M | -622K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RVMD Cash Flow Statement
Revolution Medicines, Inc. (RVMD) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -25.15M | 1.21M | -49.62M | -100.06M | -147.18M | -224.4M | -350.57M | -557.44M | -897.74M | -1.06B |
Operating CF Margin % | - | 6.02% | -99.15% | -232.8% | -500.78% | -634.26% | -3027.39% | - | - | - |
Operating CF Growth % | - | 104.82% | -4190.35% | -101.68% | -47.09% | -52.47% | -56.23% | -59.01% | -61.05% | -312.44% |
Net Income | -31.13M | -41.79M | -47.66M | -108.16M | -187.09M | -248.71M | -436.37M | -600.09M | -1.13B | -1.37B |
Depreciation & Amortization | 1.19M | 1.76M | 3.34M | 6.54M | 7.33M | 9.66M | 9.31M | 11.82M | -26.96M | 46M |
Stock-Based Compensation | 141K | 855K | 3.16M | 8.89M | 20.72M | 31.2M | 61.77M | 79.2M | 118.39M | 93.31M |
Deferred Taxes | 0 | 201K | -4.37M | -375K | 0 | -419K | -3.91M | -762K | 0 | 0 |
Other Non-Cash Items | 549K | 2.12M | 373K | 1.34M | 3.13M | -2.64M | -22.04M | -48.77M | 55.31M | 107.48M |
Working Capital Changes | 4.65M | 38.06M | -4.46M | -8.3M | 8.72M | -13.49M | 40.66M | 1.17M | 86.82M | 67.44M |
Change in Receivables | 0 | -7.3M | -1.43M | 2.34M | 464K | 1.26M | 3.42M | 1.25M | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | -2.34M | 7.68M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.97M | 109K | 5.26M | 305K | 2.24M | 7.29M | 32.47M | -6.46M | 9.54M | 34.66M |
Cash from Investing | -1.57M | -1.34M | -101.97M | -234.23M | -142.12M | -24.12M | -342.6M | -554.39M | 118.06M | 306.62M |
Capital Expenditures | -1.57M | -1.5M | -2.59M | -2.93M | -6.53M | -10.82M | -7.73M | -10.31M | -15.99M | -14.26M |
CapEx % of Revenue | - | 7.43% | 5.17% | 6.82% | 22.21% | 30.57% | 66.74% | - | - | - |
Acquisitions | 0 | 160K | 6.2M | 231.3M | 135.59M | 13.3M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | -231.3M | -135.59M | -13.3M | 0 | 0 | 0 | 0 |
Cash from Financing | 22.66M | 60.85M | 98.66M | 422.78M | 294.18M | 301.43M | 1.23B | 959.41M | 621.52M | 859.39M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 244.22M | 244.22M |
Equity Issued (Net) | 0 | 60.56M | 98.66M | 420.07M | 291.24M | 298.05M | 392.39M | 959.13M | 377.09M | 614.94M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -131K | -45K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 22.66M | 289K | 0 | 2.71M | 2.94M | 3.39M | 836.81M | 284K | 220K | 238K |
Net Change in Cash | -4.06M▲ 0% | 60.72M▲ 1595.2% | -52.93M▼ 187.2% | 88.48M▲ 267.2% | 4.88M▼ 94.5% | 52.91M▲ 983.9% | 534.74M▲ 910.6% | -153.08M▼ 128.6% | -158.16M▼ 3.3% | 108.55M▲ 0% |
Free Cash Flow | -26.72M▲ 0% | -286K▲ 98.9% | -52.2M▼ 18153.5% | -103M▼ 97.3% | -153.71M▼ 49.2% | -235.22M▼ 53.0% | -358.3M▼ 52.3% | -567.74M▼ 58.5% | -913.73M▼ 60.9% | -1.07B▲ 0% |
FCF Margin % | - | -1.42% | -104.32% | -239.62% | -522.99% | -664.83% | -3094.14% | - | - | - |
FCF Growth % | - | 98.93% | -18153.5% | -97.29% | -49.24% | -53.03% | -52.33% | -58.45% | -60.94% | -78.11% |
FCF per Share | -0.73 | -0.01 | -1.43 | -1.55 | -2.11 | -2.92 | -3.17 | -3.38 | -4.81 | -5.41 |
FCF Conversion (FCF/Net Income) | 0.81x | -0.03x | 1.04x | 0.93x | 0.79x | 0.90x | 0.80x | 0.93x | 0.79x | 0.78x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RVMD Key Ratios
Revolution Medicines, Inc. (RVMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -82.6% | -38.25% | -34.49% | -34.74% | -38.63% | -34.75% | -29.33% | -58.07% | -83.22% |
Return on Invested Capital (ROIC) | -266.82% | -49.77% | -30.81% | -29.26% | -33.73% | -40.46% | -33.62% | -54.33% | -72.29% |
Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | - | - | - |
Net Margin | -207.24% | -95.25% | -251.63% | -636.58% | -702.95% | -3768.28% | - | - | - |
Debt / Equity | 0.00x | - | 0.07x | 0.11x | 0.09x | 0.05x | 0.06x | 0.10x | 0.10x |
Interest Coverage | -359.25x | -489.92x | -1527.59x | -15589.92x | - | -1607.87x | - | -45.69x | -81.62x |
FCF Conversion | -0.03x | 1.04x | 0.93x | 0.79x | 0.90x | 0.80x | 0.93x | 0.79x | 0.78x |
Revenue Growth | - | 148.16% | -14.1% | -31.62% | 20.38% | -67.27% | -100% | - | - |
Related:RVMD Dividend History·RVMD Revenue History·RVMD Price History·RVMD P/E History·RVMD Financial Ratios·RVMD Institutional Holders
RVMD SEC Filings & Documents
Revolution Medicines, Inc. (RVMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
RVMD Frequently Asked Questions
Revolution Medicines, Inc. (RVMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Revolution Medicines, Inc. (RVMD) grew revenue by 0.0% over the past year. Growth has been modest.
Revolution Medicines, Inc. (RVMD) reported a net loss of $1.37B for fiscal year 2025.
Dividend & Returns
Revolution Medicines, Inc. (RVMD) has a return on equity (ROE) of -58.1%. Negative ROE indicates the company is unprofitable.
Revolution Medicines, Inc. (RVMD) had negative free cash flow of $1.07B in fiscal year 2025, likely due to heavy capital investments.